未经授权:头颈部小细胞癌(HNSmCC)的基本信息,包括流行病学,主站点,治疗,由于罕见,预后仍然稀疏。我们在这里报道了一项关于诊断的多中心回顾性研究,治疗,以及HNSmCC患者的预后。
UNASSIGNED:本研究涉及来自10个参与机构的47名HNSmCC患者。排除了八名患者,他们没有可用的病理标本(n=2)和中枢病理判断不一致(n=6)。其余39例患者进行数据分析。
未经评估:作为预处理检查,对大脑进行计算机断层扫描(CT)(n=8),颈部(n=39),和胸部(n=32),磁共振成像(MRI)的大脑(n=4)和颈部(n=23),23例患者的正电子发射断层扫描-CT(PET-CT),骨闪烁显像4例,颈部超声检查9例,肿瘤标志物25例。主要部位为口腔(n=1),鼻腔/鼻旁窦(n=16),鼻咽(n=2),口咽(n=4),下咽(n=2),喉(n=6),唾液腺(n=3),甲状腺(n=2),和其他人(n=3)。阶段为II/III/IV-A/IV-B/IV-C/未测定=3/5/16/6/5/4;阶段IV占69%。无患者发生脑转移。将一线治疗分为3组:放化疗(CRT)组(n=27),非CRT组(n=8),和最佳支持治疗组(n=4)。CRT组包括并发CRT(CCRT)(n=17),化疗(化疗)后放疗(RT)(n=5),和手术(Surg),然后进行CCRT(n=5)。非CRT组包括Surg,然后是RT(n=2),Surg,然后是Chemo(n=1),单独RT(n=2),和单独化疗(n=3)。所有39例患者的1年/2年总生存率(OS)为65.3/53.3%。CRT组的1年OS(77.6%)明显优于非CRT组(31.3%)。CCRT组(n=22)和无并发RT的Chemo组(n=9)之间的不良事件没有显着差异。
未经证实:颈部和胸部CT,颈部MRI,在HNSmCC的诊断设置中,PET-CT将是必要和充分的检查。CCRT可推荐作为一线治疗。1年/2年OS为65.3%/53.3%。这项研究将为提出HNSmCC的诊断和治疗算法提供基础数据。
UNASSIGNED: Basal information of head and neck small-cell carcinoma (HNSmCC) including epidemiology, primary site, treatment, and prognosis remains sparse due to its rarity. We report here a multicenter retrospective
study on the diagnosis, treatment, and outcomes of patients with HNSmCC.
UNASSIGNED: This
study involved 47 patients with HNSmCC from 10 participating institutions. Eight patients were excluded for whom no pathological specimens were available (n = 2) and for discrepant central pathological judgements (n = 6). The remaining 39 patients were processed for data analysis.
UNASSIGNED: As pretreatment examinations, computed tomography (CT) was performed for the brain (n = 8), neck (n = 39), and chest (n = 32), magnetic resonance imaging (MRI) for the brain (n = 4) and neck (n = 23), positron emission tomography-CT (PET-CT) in 23 patients, bone scintigraphy in 4, neck ultrasonography in 9, and tumor markers in 25. Primary sites were oral cavity (n = 1), nasal cavity/paranasal sinuses (n = 16), nasopharynx (n = 2), oropharynx (n = 4), hypopharynx (n = 2), larynx (n = 6), salivary gland (n = 3), thyroid (n = 2), and others (n = 3). Stages were II/III/IV-A/IV-B/IV-C/Not determined = 3/5/16/6/5/4; stage IV comprised 69%. No patient had brain metastases. First-line treatments were divided into 3 groups: the chemoradiotherapy (CRT) group (n = 27), non-CRT group (n = 8), and best supportive care group (n = 4). The CRT group included concurrent CRT (CCRT) (n = 17), chemotherapy (Chemo) followed by radiotherapy (RT) (n = 5), and surgery (Surg) followed by CCRT (n = 5). The non-CRT group included Surg followed by RT (n = 2), Surg followed by Chemo (n = 1), RT alone (n = 2), and Chemo alone (n = 3). The 1-year/2-year overall survival (OS) of all 39 patients was 65.3/53.3%. The 1-year OS of the CRT group (77.6%) was significantly better compared with the non-CRT group (31.3%). There were no significant differences in adverse events between the CCRT group (n = 22) and the Chemo without concurrent RT group (n = 9).
UNASSIGNED: Neck and chest CT, neck MRI, and PET-CT would be necessary and sufficient examinations in the diagnostic set up for HNSmCC. CCRT may be recommended as the first-line treatment. The 1-year/2-year OS was 65.3%/53.3%. This
study would provide basal data for a proposing the diagnostic and treatment algorithms for HNSmCC.